脂质体布比卡因腹横肌平面阻滞在DIEP皮瓣乳房再造中的效果:一项随机对照试验
单中心单盲随机对照试验纳入117例DIEP皮瓣乳房再造患者,比较标准布比卡因与脂质体布比卡因腹横肌平面阻滞。两组术后麻醉药用量无显著差异,但脂质体布比卡因组术后平均疼痛评分显著更低(4.3 vs 3.6,P=0.004),住院时间和麻醉药处方续配率相当。
要点
- 脂质体布比卡因组术后平均疼痛评分显著低于对照组(4.3 vs 3.6,P=0.004)。
- 两组平均麻醉药用量无显著差异(66.9 vs 60.2 吗啡毫克当量,P=0.47)。
- 住院时间(2.1 vs 2.2天,P=0.55)和麻醉药处方续配率(22% vs 17.2%,P=0.52)相当。
核心结论
- 在标准化加速康复外科方案中,标准布比卡因腹横肌平面阻滞混合液加入脂质体布比卡因,与单用标准布比卡因相比,未显著减少DIEP皮瓣乳房再造术后麻醉药需求。
- 脂质体布比卡因组患者报告的疼痛评分在术后初始24小时后更低,与镇痛持续时间更长一致。
研究设计与样本
- 单中心、单盲随机对照试验,2021年3月至2022年12月纳入117例接受DIEP皮瓣乳房再造的患者(对照组59例,试验组58例)。
- 患者随机接受术中腹横肌平面阻滞:对照组用布比卡因加肾上腺素,试验组用脂质体布比卡因、布比卡因加肾上腺素。
- 主要结局为术后麻醉药需求,次要结局为疼痛评分、住院时间和麻醉药处方续配。
主要发现
- 对照组术后平均疼痛评分显著高于试验组(4.3 vs 3.6;P=0.004)。
- 两组平均麻醉药用量无显著差异(66.9 vs 60.2 吗啡毫克当量;P=0.47)。
- 两组住院时间相当(2.1天 vs 2.2天,P=0.55),术后麻醉药处方续配率相当(22% vs 17.2%,P=0.52)。
- 两组人口学特征、合并症、乳腺病理变量、手术侧别及即刻与延期再造状态均衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transversus abdominis plane (TAP) blocks improve pain control and reduce narcotic medication requirements in various surgical procedures. Liposomal bupivacaine may provide more sustained analgesia. This study compared pain-related outcomes between standard bupivacaine and liposomal bupivacaine TAP blocks after autologous breast reconstruction. METHODS: The authors conducted a single-center, single-blinded randomized controlled trial between March of 2021 and December of 2022. Patients undergoing deep inferior epigastric perforator flap breast reconstruction in a standardized enhanced recovery after surgery pathway were randomized to receive intraoperative TAP blocks with either bupivacaine and epinephrine (control group) or liposomal bupivacaine, bupivacaine, and epinephrine (experimental group). Primary outcome was postoperative narcotic medication requirements, with secondary outcomes of pain scores, length of stay, and narcotic medication refills. RESULTS: A total of 117 patients met inclusion criteria (59 control patients and 58 experimental patients). Demographic characteristics, comorbidities, breast pathologic variables, surgery laterality, and immediate versus delayed reconstruction status were equivalent between groups. The control group had significantly higher average pain scores postoperatively (4.3 versus 3.6; P = 0.004). However, there were no significant differences in mean narcotic use (66.9 morphine milligram equivalents versus 60.2 morphine milligram equivalents; P = 0.47). Both length of stay and postoperative narcotic prescription refills were equivalent between groups (2.1 days versus 2.2 days, P = 0.55; 22% versus 17.2%, P = 0.52). CONCLUSIONS: The addition of liposomal bupivacaine to the standard bupivacaine TAP block mixture in a standardized enhanced recovery after surgery protocol did not demonstrate a significant reduction in postoperative narcotic requirements after deep inferior epigastric perforator flap breast reconstruction compared with standard bupivacaine alone. Patient-reported pain scores, however, were lower among liposomal bupivacaine patients after the initial 24 hours postoperatively and consistent with a longer duration of analgesia. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
引用
- Park RH, Chou J, DeVito RG, et al. Effectiveness of Liposomal Bupivacaine Transversus Abdominis Plane Block in DIEP Flap Breast Reconstruction: A Randomized Controlled Trial. Plast Reconstr Surg. 2024. PMID: 38315156. doi:10.1097/PRS.0000000000011326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。